Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 947934, 8 pages
http://dx.doi.org/10.1155/2015/947934
Research Article

BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients

1Department of Clinical Sciences in Lund, Section of Respiratory Medicine and Allergology, Lund University and Skane University Hospital, 221 85 Lund, Sweden
2Department of Clinical Sciences in Lund, Section of Nephrology, Lund University, 221 85 Lund, Sweden
3Department of Medicine and Health, Linköping University, 581 83 Linköping, Sweden
4Department of Nephrology UHL, County Council of Östergötland, 581 83 Linköping, Sweden

Received 23 April 2015; Revised 28 June 2015; Accepted 7 July 2015

Academic Editor: Stuart Berzins

Copyright © 2015 Ulrika Lindberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. R. Kosorok, L. Zeng, S. E. H. West et al., “Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition,” Pediatric Pulmonology, vol. 32, no. 4, pp. 277–287, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. Li, M. R. Kosorok, P. M. Farrell et al., “Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis,” Journal of the American Medical Association, vol. 293, no. 5, pp. 581–588, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Hoiby, “Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey,” Acta Pathologica et Microbiologica Scandinavica. Supplement, no. 262, pp. 1–96, 1977. View at Google Scholar · View at Scopus
  4. T. Pressler, F. Karpati, M. Granström et al., “Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods,” Journal of Cystic Fibrosis, vol. 8, no. 1, pp. 37–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. M. Mauch, C. L. Rossi, J. D. Ribeiro, A. F. Ribeiro, M. T. Nolasco da Silva, and C. E. Levy, “Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA),” Diagnostic Pathology, vol. 9, no. 1, article 158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Ratjen, H. Walter, M. Haug, C. Meisner, H. Grasemann, and G. Döring, “Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients,” Pediatric Pulmonology, vol. 42, no. 3, pp. 249–255, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. T. Zemanick, J. Emerson, V. Thompson et al., “Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis,” Pediatric Pulmonology, vol. 50, no. 1, pp. 42–48, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. S. E. H. West, L. Zeng, B. L. Lee et al., “Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors,” The Journal of the American Medical Association, vol. 287, no. 22, pp. 2958–2967, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Daines, D. VanDeVanter, U. Khan et al., “Serology as a diagnostic tool for predicting initial Pseudomonas aeruginosa acquisition in children with cystic fibrosis,” Journal of Cystic Fibrosis, vol. 13, no. 5, pp. 542–549, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Kappler, A. Kraxner, D. Reinhardt, B. Ganster, M. Griese, and T. Lang, “Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis,” Thorax, vol. 61, no. 8, pp. 684–688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. R. M. Mauch and C. E. Levy, “Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: a systematic review,” Journal of Cystic Fibrosis, vol. 13, no. 5, pp. 499–507, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. M. H. Zhao, S. J. Jones, and C. M. Lockwood, “Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis,” Clinical and Experimental Immunology, vol. 99, no. 1, pp. 49–56, 1995. View at Google Scholar · View at Scopus
  13. J. Weiss, P. Elsbach, I. Olsson, and H. Odeberg, “Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes,” Journal of Biological Chemistry, vol. 253, no. 8, pp. 2664–2672, 1978. View at Google Scholar · View at Scopus
  14. P. Elsbach, “The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense,” Journal of Leukocyte Biology, vol. 64, no. 1, pp. 14–18, 1998. View at Google Scholar · View at Scopus
  15. P. Elsbach and J. Weiss, “Role of the bactericidal/permeability-increasing protein in host defence,” Current Opinion in Immunology, vol. 10, no. 1, pp. 45–49, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. M. H. Zhao, D. R. W. Jayne, L. G. Ardiles, F. Culley, M. E. Hodson, and C. M. Lockwood, “Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis,” QJM, vol. 89, no. 4, pp. 259–265, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Schultz and J. P. Weiss, “The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease,” Clinica Chimica Acta, vol. 384, no. 1-2, pp. 12–23, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. N. M. Iovine, P. Elsbach, and J. Weiss, “An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 20, pp. 10973–10978, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. M. P. Stoffel, E. Csernok, C. Herzberg, T. Johnston, S. F. Carroll, and W. L. Gross, “Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders,” Clinical and Experimental Immunology, vol. 104, no. 1, pp. 54–59, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Šedivá, J. Bartůňková, I. Kolářová et al., “Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis,” Journal of Autoimmunity, vol. 11, no. 2, pp. 185–190, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Mahadeva, A. C. Dunn, R. C. Westerbeek et al., “Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease,” Clinical and Experimental Immunology, vol. 117, no. 3, pp. 561–567, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Carlsson, L. Eriksson, T. Pressler et al., “Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis,” Journal of Cystic Fibrosis, vol. 6, no. 3, pp. 228–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Schultz, S. Schinke, K. Mosler, K. Herlyn, A. Schuster, and W. L. Gross, “BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5α in vitro,” Pediatric Pulmonology, vol. 37, no. 2, pp. 158–164, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. U. Lindberg, M. Carlsson, C.-G. Löfdahl, and M. Segelmark, “BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study,” Clinical and Developmental Immunology, vol. 2012, Article ID 370107, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. “Standardization of spirometry, 1994 update. American Thoracic Society,” American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 3, pp. 1107–1136, 1995. View at Publisher · View at Google Scholar
  26. P. H. Quanjer, G. J. Tammeling, J. E. Cotes, O. F. Pedersen, R. Peslin, and J. C. Yernault, “Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society,” The European Respiratory Journal. Supplement, vol. 16, pp. 5–40, 1993. View at Google Scholar · View at Scopus
  27. T. W. R. Lee, K. G. Brownlee, S. P. Conway, M. Denton, and J. M. Littlewood, “Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients,” Journal of Cystic Fibrosis, vol. 2, no. 1, pp. 29–34, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Rasmussen, C. Sjölin, B. Isaksson, P. Bygren, and J. Wieslander, “An ELISA for the detection of anti-neutrophil cytoplasm antibodies (ANCA),” Journal of Immunological Methods, vol. 127, no. 1, pp. 139–145, 1990. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Aanaes, N. Rasmussen, T. Pressler et al., “Extensive endoscopic image-guided sinus surgery decreases BPI-ANCA in patients with cystic fibrosis,” Scandinavian Journal of Immunology, vol. 76, no. 6, pp. 573–579, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. G. B. Winnie and R. G. Cowan, “Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function,” Pediatric Pulmonology, vol. 10, no. 2, pp. 92–100, 1991. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Kappler, F. Nagel, M. Feilcke et al., “Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment,” Journal of Cystic Fibrosis, vol. 13, no. 5, pp. 534–541, 2014. View at Publisher · View at Google Scholar
  32. M. Anstead, S. L. Heltshe, U. Khan et al., “Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial,” Journal of Cystic Fibrosis, vol. 12, no. 2, pp. 147–153, 2013. View at Publisher · View at Google Scholar · View at Scopus